Fig. 1

Effect of AT and GT3 on prostate cancer cells. a and b: LNCaP and PC-3 were treated with AT or GT3 at doses ranging from 10 to 80 μM. After 6 h of treatment, cell viability was determined via MTT. c, d and e: LNCaP, PC-3, and non-tumorigenic RWPE-1 cells underwent the same treatment as described above for 12 h. All graphs shown correspond to data obtained by analysis of metabolic activity from at least three independent experiments. For quantification spectrophotometric data were calculated as percentages of the value for the untreated cells (100%) ± standard deviations n = 3, *p < 0.05, **p < 0.01